Saidi Odoma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saidi Odoma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Awafung Emmanuel Adie
Department of Biomedical Engineering, Kampala International University, Western Campus, Bushenyi Ishaka, Uganda
1 shared publication Gilbert Bwire
Department of Pharmacology and Toxicology, Kampala International University, Ishaka-Bushenyi, Uganda
1 shared publication- Ibrahim Babangida Abubakar
Biochemistry, Kampala International University - Western Campus, Bushenyi, Western Region
1 shared publication - Josiah Eseoghene Ifie
Valley University Faculty of Science amd technology, Bushenyi
1 shared publication - Kelechi John Ukagwu
Department of Electrical, Telecommunication, and Computer Engineering, Kampala International University, Western Campus, Bushenyi Ishaka, Uganda
1 shared publication - Nansamba Fridah Mirembe
Department of Nursing Science, Kampala International University, Western Campus, Ishaka, Uganda
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51105
Numerical investigation of the impact of neural stem cells on brain tumors
Malignant brain tumors, including glioblastoma and medulloblastoma, remain highly treatment-resistant. Neural stem cells (NSCs) are being investigated as tumor-tropic therapeutic vectors, but the temporal interaction between tumor and NSC populations requires quantitative characterization before model-based treatment hypotheses can be interpreted reliably. This study aimed to develop and numerically evaluate a reproducible 2-population model of tumor–NSC dynamics and to quantify the influence of NSC persistence and NSC-mediated tumor killing on simulated tumor burden. A normalized system of 2 coupled nonlinear ordinary differential equations was used: dT / dt = rT (1 − T ) − β T N and d N/ dt = αN(1 − N) − γ T N. The baseline simulation used r = 0.20000 day −1 , α = 0.05000 day −1 , β = 0.35000 day −1 , γ = 0.30000 day −1 , T 0 = 0.50000, and N 0 = 0.40000. Explicit Euler integration was performed with Δ t = 0.01 day over 20 days. A descriptive nonlinear regression fit, Fourier spectral analysis, 1-parameter sensitivity analyses, and joint α–β sensitivity analysis were applied to the simulated trajectory. In the baseline simulation, tumor density decreased from 0.5000 to a minimum of 0.4772 at day 2.59 (4.57% below the initial value) and subsequently increased to T 20 = 0.8273, while NSC density declined from 0.4000 to N 20 = 0.0247. The descriptive regression reproduced the simulated tumor trajectory with R 2 = 0.9973 and root mean square error = 0.00590. Increasing α from 0.05 to 0.10 day −1 reduced T 20 by 12.6% relative to baseline, and increasing β from 0.35 to 0.50 day −1 reduced T 20 by 19.9%. Jointly setting α = 0.10 and β = 0.50 day −1 yielded T 20 = 0.4427, 46.5% below the baseline terminal tumor density. The Fourier spectrum was dominated by the zero and low-frequency components, with no distinct oscillatory peak over the 20-day window. The model indicates that NSC persistence and NSC-mediated tumor killing materially influence terminal tumor burden, but the baseline parameterization produces only transient early suppression followed by tumor regrowth as the NSC population declines. The results are population-level, model-based estimates rather than tumor-type-specific clinical efficacy measures. Tumour-specific calibration, spatial migration, immune interactions, and experimental validation are required before translational conclusions can be drawn.
- 16 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (42) , e51105
Open AccessNumerical investigation of the impact of neural stem cells on brain tumors
Malignant brain tumors, including glioblastoma and medulloblastoma, remain highly treatment-resistant. Neural stem cells (NSCs) are being investigated as tumor-tropic therapeutic vectors, but the temporal interaction between tumor and NSC populations requires quantitative characterization before model-based treatment hypotheses can be interpreted reliably. This study aimed to develop and numerically evaluate a reproducible 2-population model of tumor–NSC dynamics and to quantify the influence of NSC persistence and NSC-mediated tumor killing on simulated tumor burden. A normalized system of 2 coupled nonlinear ordinary differential equations was used: dT / dt = rT (1 − T ) − β T N and d N/ dt = αN(1 − N) − γ T N. The baseline simulation used r = 0.20000 day −1 , α = 0.05000 day −1 , β = 0.35000 day −1 , γ = 0.30000 day −1 , T 0 = 0.50000, and N 0 = 0.40000. Explicit Euler integration was performed with Δ t = 0.01 day over 20 days. A descriptive nonlinear regression fit, Fourier spectral analysis, 1-parameter sensitivity analyses, and joint α–β sensitivity analysis were applied to the simulated trajectory. In the baseline simulation, tumor density decreased from 0.5000 to a minimum of 0.4772 at day 2.59 (4.57% below the initial value) and subsequently increased to T 20 = 0.8273, while NSC density declined from 0.4000 to N 20 = 0.0247. The descriptive regression reproduced the simulated tumor trajectory with R 2 = 0.9973 and root mean square error = 0.00590. Increasing α from 0.05 to 0.10 day −1 reduced T 20 by 12.6% relative to baseline, and increasing β from 0.35 to 0.50 day −1 reduced T 20 by 19.9%. Jointly setting α = 0.10 and β = 0.50 day −1 yielded T 20 = 0.4427, 46.5% below the baseline terminal tumor density. The Fourier spectrum was dominated by the zero and low-frequency components, with no distinct oscillatory peak over the 20-day window. The model indicates that NSC persistence and NSC-mediated tumor killing materially influence terminal tumor burden, but the baseline parameterization produces only transient early suppression followed by tumor regrowth as the NSC population declines. The results are population-level, model-based estimates rather than tumor-type-specific clinical efficacy measures. Tumour-specific calibration, spatial migration, immune interactions, and experimental validation are required before translational conclusions can be drawn.
- Open Access
- 12 April 2025
- Published by Department of Pharmacology & Toxicology, Faculty of Pharmacy, University of Benin in Pharmacology and Toxicology of Natural Medicines
- Vol. 5 (1-2) , 20-24
Elucidation of the Possible Mechanism of Antinociceptive Action of Methanol Stem Bark Extract of Zanthoxylum gilletii (De Wild.) in Mice
Background and Purpose: Zanthoxylum gilletii (De Wild.) stem bark is used traditionally for pain management, but its antinociceptive activity is yet to be validated. This study evaluated the antinociceptive activity and elucidated the possible mechanism of antinociceptive action of its methanol stem bark extract. Methods: Oral acute toxicity was evaluated using Lorke’s method, while antinociceptive activity was assessed using acetic acid-induced writhing test. Mice were randomly assigned to groups receiving distilled water, morphine (10 mg/kg), or the extract (250 and 500 mg/kg). Mechanistic studies involved pre-treating mice with naloxone (2 mg/kg), glibenclamide (5 mg/kg), or propranolol (20 mg/kg) 15 min before the extract (500 mg/kg), followed by acetic acid administration. Results: No mortality or signs of toxicity were observed at acute oral doses up to 5,000 mg/kg. The extract significantly (P<0.01) reduced writhing counts in a dose-dependent manner, with effects reversed by naloxone (P<0.05), enhanced by propranolol and unaffected by glibenclamide. Conclusion: Zanthoxylum gilletii extract has a high oral safety margin, with an LD?? exceeding 5,000 mg/kg. The antinociceptive activity of the extract may involve opioid receptor activation, but not beta-adrenergic pathway or ATP-sensitive potassium channels. Further studies would determine its bioactive components.
- 12 April 2025
- Published by Department of Pharmacology & Toxicology, Faculty of Pharmacy, University of Benin in Pharmacology and Toxicology of Natural Medicines
- Vol. 5 (1-2) , 20-24
Open AccessElucidation of the Possible Mechanism of Antinociceptive Action of Methanol Stem Bark Extract of Zanthoxylum gilletii (De Wild.) in Mice
Background and Purpose: Zanthoxylum gilletii (De Wild.) stem bark is used traditionally for pain management, but its antinociceptive activity is yet to be validated. This study evaluated the antinociceptive activity and elucidated the possible mechanism of antinociceptive action of its methanol stem bark extract. Methods: Oral acute toxicity was evaluated using Lorke’s method, while antinociceptive activity was assessed using acetic acid-induced writhing test. Mice were randomly assigned to groups receiving distilled water, morphine (10 mg/kg), or the extract (250 and 500 mg/kg). Mechanistic studies involved pre-treating mice with naloxone (2 mg/kg), glibenclamide (5 mg/kg), or propranolol (20 mg/kg) 15 min before the extract (500 mg/kg), followed by acetic acid administration. Results: No mortality or signs of toxicity were observed at acute oral doses up to 5,000 mg/kg. The extract significantly (P<0.01) reduced writhing counts in a dose-dependent manner, with effects reversed by naloxone (P<0.05), enhanced by propranolol and unaffected by glibenclamide. Conclusion: Zanthoxylum gilletii extract has a high oral safety margin, with an LD?? exceeding 5,000 mg/kg. The antinociceptive activity of the extract may involve opioid receptor activation, but not beta-adrenergic pathway or ATP-sensitive potassium channels. Further studies would determine its bioactive components.